Medicaid Covers GLP-1 Meds for Obesity in Just 13 States
Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Among those states that don’t cover the drugs, half reported that they are considering adding ...
Medicaid covers GLP-1 weight-loss drugs in just 13 states
Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Advertisement Under the Medicaid system, individual states are allowed to decide whether to cover GLP-1 ...
Map Shows States Where Weight Loss Drugs are Most Popular
Kentucky, Alaska and Alabama are the three states where weight loss drugs are most used, and Hawaii, Arizona and Colorado sit at the other end of the spectrum, a report has revealed. Glucagon-like peptide-1 (GLP-1) receptor analogs are drugs that mimic fullness hormone GLP-1 and have been shown to reduce appetite,
Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs
These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people eat less,
States slow to cover GLP-1s for weight loss
Axios Visuals Budget pressures have kept all but 13 states from covering GLP-1 drugs for weight loss through their Medicaid programs, a new report from KFF shows. Why it matters: The restrictive policies add to equity concerns around the blockbuster drugs,
Hosted on MSN3h
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
GLP-1s, or glucagon-like peptide-1 agonist drugs, are seemingly everywhere. In recent years, this class of weight-loss and Type 2 diabetes medication has become not only a household name but ...
HealthDay on MSN1h
Guidance Issued for Safe Use of GLP-1 RAs in the Perioperative Period
In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...
Improvement seen in some features of PCOS with weight loss interventions
Weight loss interventions are associated with improvement in some features of polycystic ovary syndrome (PCOS), according to ...
Too Old to Operate7d
Glucagon-like peptide-1 receptor agonists may impact outcomes of endoscopy
The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not ...
Neurology Advisor1d
Risk for Suicidal Ideation, Attempts Down With GLP1-RA Treatment in Teens With Obesity
For adolescents with obesity, GLP1-RA treatment is associated with a reduced risk for suicidal ideation or attempts.
AOL18h
4 Ways to Prevent Muscle Loss on Ozempic & Other Weight Loss GLP-1 Medications
You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor ...
EurekAlert!20d
Ozempic (and similar medications) may be the new treatment for opioid and alcohol use disorder
Ozempic is one of several medications, called glucagon-like peptide-1 receptor agonists or GLP-1 RAs, that are prescribed to treat diabetes, obesity, and other weight-related medical conditions.
Medscape4d
The Glucagonostatic and Insulinotropic Effects of Glucagon-like Peptide 1 Contribute Equally to its Glucose-lowering Action
Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...
2minutemedicine.com6d
Glucagon-like peptide 1 receptor agonists may decrease rates of inflammatory bowel disease flares
The use of glucagon-like peptide 1 (GLP-1) agonists in patients with inflammatory bowel disease (IBD) was associated with few ...
GlobalData on MSN10h
Viking stock fluctuates amid manufacturing concerns with obesity pill
Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.